NCT04859517Phase 2, phase 3Terminated

Evaluation of ADG20 for the Prevention of COVID-19

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-11-04Actual

Enrollment · participants2582Actual

Source updated2024-08-20Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

COVID-19

Treatments or interventions studied

ADG20Drug
PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP); description: RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCR test from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.; timeFrame: Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier; measure: Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PrEP); description: RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCR test from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.; timeFrame: Day 1 through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier; measure: Solicited Injection Site Reactions (PEP, PrEP); description: Percentage of participants with at least one solicited injection site reaction; timeFrame: Day 1 through Day 4; measure: Participants With at Least 1 Treatment Emergent Adverse Events (PEP, PrEP); description: Any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment; includes solicited injection site reactions; timeFrame: Day 1 through 14 Months or 25Jul2022, whichever is earlier

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history